Zhuldyz Nurmykhametova

Dr. Zhuldyz Nurmykhametova

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2018 in Artificial Organs
Verified
Journal Article
Open access
PDF file
RKRymbay Kaliyev
Rymbay Kaliyev
SBSerik Bekbossynov
Serik Bekbossynov
ZNZhuldyz Nurmykhametova
Zhuldyz Nurmykhametova

27 October 2020 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
RKRymbay Kaliyev
Rymbay Kaliyev
TLTimur Lesbekov
Timur Lesbekov
SBSerik Bekbossynov
Serik Bekbossynov
ZNZhuldyz Nurmykhametova
Zhuldyz Nurmykhametova
MBMakhabbat Bekbossynova
Makhabbat Bekbossynova
YPYuriy Pya
Yuriy Pya
Background: Organ Care System (OCS) minimizes the cold ischemic time and allows for optimization of logistics and meticulous recipient preparation. Impact of normothermic ex-vivo preservation using OCS compared with cold storage (CS) for prolonged heart preservation especially beneficial for high-risk recipients bridged to transplantation with Mechanical Circulatory Support (MCS). Methods: Between 2012 and 2018, we performed a retrospective single-center review of prospectively collected data. All patients who underwent heart transplantation with MCS using the OCS Heart (n = 25) versus standard cold storage (n = 10) were included in this study. Results: During this period, 353 patients were implanted with left ventricular assisted device (LVAD) and 35 (10%) were bridged to heart transplantation. There was no significant difference in donor and recipient characteristics and risk factors. The Index for Mortality Prediction after Cardiac Transplantation (IMPACT) score was a trend towards higher estimated risk of death at 1y in the OCS group (14.2 vs. 10.8% p = 0.083). Mean total ischemic time during preservation was statistically significantly longer in CS vs OCS group (210 (23) Vs 74.6 (13) min p = 0.001). Median ex vivo normothermic heart perfusion time in OCS was 348.4(132; 955) min. There was significant difference in total out of body time between OCS group 423(67) Vs CS group 210(23) min p = 0.002). All patients were alive on the 30th days post implant in CS groups and 96% in OCS group (p = 0.5). Conclusion: Normothermic ex-vivo preservation of the allograft during transportation with the organ care system might be beneficial for long-time out of body organ preservation in comparison of cold storage especially for recipients on mechanical circulatory support.

23 July 2019 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
RKRymbay Kaliyev
Rymbay Kaliyev
TLTimur Lesbekov
Timur Lesbekov
SBSerik Bekbossynov
Serik Bekbossynov
MBMakhabbat Bekbossynova
Makhabbat Bekbossynova
ZNZhuldyz Nurmykhametova
Zhuldyz Nurmykhametova
YPYuriy Pya
Yuriy Pya
Objectives: Cold crystalloid cardioplegia for donor heart harvesting and cold ischemic storage conditions during the transportation is the standard of care during heart transplantation procedure. Organ care system (OCS) was introduced for more prolonged and reliable ex vivo organ management. This study evaluated the two different techniques used for myocardial preservation during the procurement and transportation of the heart using the OCS. Methods: We performed prospective analysis of 43 patients with heart failure undergoing heart transplantation and using the OCS for donor organ transport. Donor hearts were arrested using blood cardioplegia and conditioning ( n = 30) or standard Custodiol (SC) solution ( n = 13). Perfusion and cardiac function parameters were continuously monitored while the donor hearts were perfused in the OCS. Impact of preservation techniques on biochemical parameters and clinical outcomes were evaluated. Results: All donor hearts had stable perfusion and lactate characteristics in the OCS, with similar measures between the two groups at the beginning of the ex vivo perfusion. Ex vivo heart perfusion mean ending concentration of Interleukin (IL)‐6 and IL‐8 was significantly lower in the blood cardioplegia group compared to the standard care group. Clinical outcomes were comparable between the two groups of patients. Conclusions: The use of blood cardioplegia and conditioning could be a safe method for myocardial protection in distant procurement and preservation of donor hearts in the OCS.

25 November 2022 in Artificial Organs
Verified
Journal Article
Open access
TLTimur Lesbekov
Timur Lesbekov
ZNZhuldyz Nurmykhametova
Zhuldyz Nurmykhametova
RKRymbay Kaliyev
Rymbay Kaliyev
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
LFLinar Faizov
Linar Faizov
YPYuriy Pya
Yuriy Pya
Background: ECMO support is associated with the development of a systemic hyper‐inflammatory response, which may become quite significant and extreme in some cases. We hypothesize that Cytosorb or Jafron therapy may benefit patients on V‐A ECMO in terms of levels of inflammatory markers such as IL‐6, complications, and overall outcomes.Methods: We conducted a retrospective study of prospectively collected data in a single tertiary care center between January 2021 and April 2022. At the time of the analysis of this article, 20 patients on V‐A ECMO had cytokine adsorption while on ECMO support: Cytosorb group (n = 10), Jafron group (n = 10). In 10 ECMO‐supported patients cytokine adsorption was not used, this group served as a control group, which may be quite significant in some cases. Evaluation of the level of inflammatory markers (IL‐1, 6, 8; CRP, Leukocyte, Lactate, PCT, NT‐proBNP, TNF‐α) was performed.Results: There was statistically significant longer CPB time, aortic cross‐clamp time and ICU stay in cytokine adsorption groups than in the control group, but there were no differences between subgroups with different types of haemoadsorption used. Moreover, in the control group mortality rate was higher than in the cytokine adsorption groups (60% vs. 20%, p = 0.02). All patients had an elevation of inflammatory markers in the perioperative and immediate postoperative periods. After 72 h of intensive care, blood inflammation markers had a tendency to decline.Conclusion: At the time of writing, hemadsorption in patients requiring V‐A ECMO support represents a good therapeutic effect. This effect is permanent for the whole period of extracorporeal cytokine hemadsorption application for both CytoSorb and Jafron HA330 devices.

20 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TLTimur Lesbekov
Timur Lesbekov
AMAbdurashid Mussayev
Abdurashid Mussayev
ASAliya Sailybayeva
Aliya Sailybayeva
RKRymbay Kaliyev
Rymbay Kaliyev
AKAidyn Kuanyshbek
Aidyn Kuanyshbek
SKSadyk Khamitov
Sadyk Khamitov
Introduction: TAVR remains a complex procedure that may result in serious intraprocedural complications. In many of these circumstances, venoarterial extracorporeal membrane oxygenation (V-A ECMO) helps to manage complications, provides a hemodynamic back-up, and bridges to an emergency open heart surgery. The clinical outcomes of 27 patients who underwent prophylactic implantation of peripheral V-A ECMO (pV-A ECMO) during high-risk transcatheter aortic valve replacement (TAVR) cases are described. Methods: From June 2012 to October 2022, 590 consecutive patients underwent TAVR at our center. Of these, 27 patients (4.5%) underwent TAVR with pV-AECMO because they were deemed very high risk for periprocedural complications and formed the study population. Results: There were no pV-A ECMO, hemodynamic or TAVR implantation complications. Decannulation of the ECMO system was performed in 92.6% of cases at the end of the procedure in the hybrid-operating theatre. The mean duration of pV-A ECMO for procedure support was 51.4 ± 10.3 min. There were no ECMO-related vascular or bleeding complications. Conclusion: This study shows that the prophylactic placement of awake peripheral V-A ECMO provides excellent temporary cardio-circulatory and pulmonary support during very high-risk TAVR procedures.

18 June 2024 in The Journal of ExtraCorporeal Technology
Verified
Journal Article
Open access
PDF file
NJNilufar Jabayeva
Nilufar Jabayeva
BBBolat Bekishev
Bolat Bekishev
TLTimur Lesbekov
Timur Lesbekov
ZNZhuldyz Nurmykhametova
Zhuldyz Nurmykhametova
RKRymbay Kaliyev
Rymbay Kaliyev
RSRobertas Samalavicius
Robertas Samalavicius
The usage of cardiopulmonary bypass (CPB) in cardiothoracic surgery contributes to the activation of the inflammatory response. In certain cases, the systemic inflammatory response may be immoderate, leading to organ dysfunction, such as acute renal failure or multiorgan dysfunction. This study aimed to examine the effect of haemoadsorption (HA) therapy on inflammatory markers and renal damage indices during cardiopulmonary bypass and in the early postoperative period. We conducted a retrospective analysis of prospectively collected data in a single tertiary care center on patients operated between January 2021 and May 2022. The levels of inflammatory markers and renal parameters in blood samples (Interleukin (IL) 6, C-reactive protein (CRP), white blood cells, lactate, procalcitonin (PCT), and NT-proBNP, urea, creatinine, glomerular filtration rate (GFR), mechanical ventilation days and intensive care unit (ICU) days) were compared between the three groups. Data from the Jafron HA 330 (n = 20) and CytoSorb300 (n = 20) groups were compared with those from the control group (n = 20). All patients underwent cardiopulmonary bypass for more than 120 min. Baseline patient characteristics were similar in all three groups. Acute kidney injury (AKI) was diagnosed in 17 patients (28.3%); seven patients were in the Jafron HA 330, two in the CytoSorb300, and eight in the control group. We found that IL1α, IL 6, IL8, Lactate dehydrogenase, PCT, NT-proBNP, CRP, Leukocyte, and TNFα had no significant or clinical difference between the CytoSorb 300 and Jafron HA 330 adsorber groups. Our results indicate that haemoadsorption therapy does not significantly reduce the risk of AKI after prolonged CPB, but decreases the need for renal replacement therapy.